QIAGEN GENEREADER
DEAD

Serial Number

86017381

Owner

QIAGEN WALTHAM, INC.

Attorney

G MATHEW LOMBARD

Filing Date

Jul 23, 2013

Add to watchlist:

No watchlists yet
View on USPTO

QIAGEN GENEREADER Trademark

Serial Number: 86017381 • Registration: 5075977

QIAGEN GENEREADER is a trademark filed by QIAGEN WALTHAM, INC. on July 23, 2013. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). The application is currently no longer active.

Owner Contact Info

QIAGEN WALTHAM, INC. (2 trademarks)

35 GATEHOUSE DRIVE
WALTHAM, MA 02451

Entity Type: 03

INTELLIGENT BIO-SYSTEMS, INC. (3 trademarks)

35 GATEHOUSE DRIVE
WALTHAM, MA 02451

Entity Type: 03

QIAGEN SCIENCES, LLC (44 trademarks)

19300 GERMANTOWN ROAD
GERMANTOWN, MD 20874

Entity Type: 16

Trademark Details

Filing Date

July 23, 2013

Registration Date

November 8, 2016

Published for Opposition

August 23, 2016

Cancellation Date

May 19, 2023

Goods & Services

Scientific apparatuses, instruments and devices and their structural parts and components therefor for analyzing and sequencing biomolecules, namely, nucleic acids; computer software for use in scientific and medical research for assisting in analyzing and sequencing biomolecules, namely, nucleic acids; scientific apparatuses, instruments and devices for analysis of nucleic acids, namely, nucleic acid sequencers

Diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; diagnostic preparations for humans for medical purposes; preparations for medical and veterinary purposes, namely, diagnostic preparations, for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing; chemical, biochemical and biotechnological preparations for medical and veterinary purposes, namely, diagnostic reagents, enzymes and diagnostic reagents in the nature of buffer solutions for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing; kits containing preparations for medical and veterinary diagnostic purposes primarily consisting of diagnostic preparations for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing

Chemical, biochemical and biotechnological products for industrial and scientific purposes, namely, diagnostic preparations except for human or veterinary medical purposes, non-medical chemical reagents, enzymes and chemicals solutions in the nature of buffer solutions for scientific and/or medical research use for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing; kits comprising chemicals for laboratory or research use for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular nucleic acids of biological or biochemical sample material, in particular comprising chemicals for reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing

Filing History

CANCELLED SEC. 8 (6-YR)
May 19, 2023 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Nov 8, 2021 REM1
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Dec 26, 2018 ASCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
May 30, 2018 ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 16, 2017 ASGN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 27, 2017 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 27, 2017 COAR
REGISTERED-PRINCIPAL REGISTER
Nov 8, 2016 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 23, 2016 NPUB
PUBLISHED FOR OPPOSITION
Aug 23, 2016 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 3, 2016 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 19, 2016 PREV
ASSIGNED TO LIE
Jul 12, 2016 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 6, 2016 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 21, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 21, 2016 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jun 16, 2016 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Dec 31, 2015 GNS2
INQUIRY TO SUSPENSION E-MAILED
Dec 31, 2015 GNSI
SUSPENSION INQUIRY WRITTEN
Dec 31, 2015 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Dec 9, 2015 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 27, 2015 RCSC
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 29, 2014 TCCA
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Nov 19, 2014 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Nov 19, 2014 RCCK
ASSIGNED TO LIE
Oct 31, 2014 ALIE
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 23, 2014 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 23, 2014 GNSL
SUSPENSION LETTER WRITTEN
Apr 23, 2014 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 22, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 21, 2014 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 21, 2014 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 5, 2013 GNRN
NON-FINAL ACTION E-MAILED
Nov 5, 2013 GNRT
NON-FINAL ACTION WRITTEN
Nov 5, 2013 CNRT
ASSIGNED TO EXAMINER
Nov 5, 2013 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 26, 2013 NWOS
NEW APPLICATION ENTERED
Jul 26, 2013 NWAP